Phase I population pharmacokinetics of irofulven

Anti-Cancer Drugs

Volumn 14, Issue 5, 2003, Pages 353-358

  Urien, S ^a,f   Alexandre, J ^b   Raymond, E ^c   Brain, E ^a   Smith, S ^d   Shah, A ^d   Cvitkovic, E ^e   Lokiec, F ^a  

^a Cancer Research Center Rene Huguenin   (France)

^b Cochin Hospital ^*  (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d GUILFORD PHARMACEUTICALS INC   (United States)

^e BICÊTRE HOSPITAL   (France)

^f CENTRE RENÉ HUGUENIN   (France)

Author keywords

Anticancer drugs; Bayesian method; Irofulven; Population pharmacokinetics

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE;

ADULT; AGED; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; BODY SURFACE; BODY WEIGHT; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG INFUSION; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADULT; AGED; ALGORITHMS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POPULATION; SAMPLING STUDIES; SESQUITERPENES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0038517703     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200306000-00005     Document Type: Article

References (11)

1. Kelner MJ, McMorris TC, Montoya MA, Estes L, Uglik SF, Rutherford M, et al. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell line. Cancer Chemother Pharmacol 1999; 44:235-240.
2. Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, et al. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol 2000; 18:4086-4097.
3. Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, et al. Phase I clinical and pharmacokinetic trial of irofulven. Cancer Chemother Pharmacol 2001; 48:467-472.
4. Urien S. MP2 (V 2.0) - a Windows application for population pharmacokinetics. In: Aarons L, Balant LP, Danhof M, Gex-Fabry M, Gundert-Remy UA, Karlsson MO, et al. (editors): The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: European Commission; 1997, pp. 419-422.
5. Tod M, Rocchisani JM. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. Comput Methods Progams Biomed 1996; 50:13-22.
6. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71:1344-1348.
7. Shoemaker RC, Cohen AF. Estimating impossible curves using NONMEM. Br J Clin Pharmacol 1996; 42:283-289.
8. Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, et al. Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther 1996; 59:436-443.
9. Freyer G, Tranchand B, Ligneau B, Ardiet C, Souquet PJ, Court-Fortune I, et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 2000; 50:315-224.
10. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14:2590-2611.
11. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998; 16:2297-2298.